The FDA-approved schizophrenia and bipolar disorder therapy met the primary and secondary endpoint in a Phase III “withdrawal ...

In a 24-week trial, semaglutide led to a 52% reduction in albuminuria and improved kidney health in individuals with chronic ...

CinFina Pharma, a CinRx portfolio company dedicated to advancing a portfolio of high-impact treatment options for obesity, today announced topline int ...

Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration ...

Source Reference: Janik A, et al "Efficacy and safety of esketamine nasal spray as monotherapy in adults with ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

The FCM protein snack bar, rich in amino acids and antioxidants, improves brain function and memory accuracy in just six ...

In patients with PAH, reducing peripheral serotonin using rodatristat ethyl negatively affects pulmonary hemodynamics and cardiac function.

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

The CardiAMP HF Trial is assessing the safety and effectiveness of the CardiAMP ® Cell Therapy System for HFrEF, with the potential to reduce all cause death, future hospitalizations, enhance ...

Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line ...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has initiated ...